PDRN and polynucleotide skin boosters explained: what salmon DNA treatments do, the July 2026 US developments, and why no injectable is FDA approved.
PDRN and polynucleotide skin boosters are salmon DNA derived injectables and serums promoted for skin repair and collagen support. In July 2026, SkinSpirit launched a topical PDRN microneedling treatment and PharmaResearch expanded its Rejuran brand in the US. No PDRN or polynucleotide injectable is FDA approved for aesthetic use.
PDRN (polydeoxyribonucleotide) and polynucleotide (PN) skin boosters are among the most talked about regenerative aesthetics of 2026, driven largely by K-beauty interest in salmon DNA. Two July 2026 developments pushed them into the US conversation: SkinSpirit rolled out a topical PDRN microneedling treatment, and PharmaResearch moved to expand its Rejuran brand stateside. This explainer defines what these products are and states their US regulatory status plainly.
The short version for US consumers: topical PDRN serums are sold as cosmetics and are not pre-approved by the FDA, while the injectable polynucleotide skin boosters popular in South Korea and Europe are not FDA approved for aesthetic use in the United States. The distinction between what is applied on the skin and what is injected under it matters a great deal here.
PDRN is a fragment of DNA, most commonly sourced from salmon or trout sperm, that is proposed to support the skin's natural repair processes by supplying nucleotides. Polynucleotides (PN) are longer chains of the same building blocks. Both are marketed for skin regeneration, hydration, collagen support, and barrier strength rather than for wrinkle relaxation or volume, which sets them apart from neurotoxins and dermal fillers.
Delivery is the key variable. In some markets, PN and PDRN are injected into the skin as a course of skin booster sessions. In the US, the same molecules appear mainly in topical serums layered with microneedling, which creates channels intended to help the ingredient penetrate. Evidence for meaningful, durable results is stronger for in office injectable protocols studied abroad than for topical use, and independent long term US data remains limited.
On July 1, 2026, SkinSpirit announced a PDRN Salmon DNA Microneedling Catalyst Serum treatment, a topical serum described as 3 percent salmon DNA paired with microneedling and available across its 60 plus US clinics. Co founder and Medical Director Dr. Dean Vistnes framed the launch around patients seeking treatments that work at a deeper biological level. The announcement did not claim FDA approval, and none applies, because topical cosmetics are not pre approved by the FDA.
Separately, PharmaResearch, the South Korean maker of the Rejuran polynucleotide line, said on July 1, 2026 that it had agreed to acquire California based Cosmetic Group USA to secure local manufacturing for its REJURAN Cosmetics topical brand, following Sephora and Amazon launches, with Canada entry planned for the second half of 2026. That expansion covers cosmetic grade topical products, not the injectable skin booster.
No PDRN or polynucleotide injectable is FDA approved for aesthetic use in the United States. These injectables do not appear on the FDA's list of approved dermal fillers, and US clinics should not market them as FDA approved. Rejuran injectable is approved in South Korea under its MFDS framework, but that approval is not portable to the US, where it has not undergone FDA review for safety and effectiveness.
Topical PDRN serums, including the SkinSpirit catalyst serum and REJURAN Cosmetics, are regulated as cosmetics, which the FDA does not pre approve before sale. Note that phrases like FDA registered or FDA compliant on a cosmetic label describe facility registration, not product approval, and can be misleading. A cosmetic serum and an injected skin booster are legally and clinically different products, even when both cite salmon DNA.
Two threads are worth following. First, whether any manufacturer pursues formal FDA clearance or approval for a polynucleotide injectable in the US, which would change the picture; as of July 2026 none has been approved. Second, how topical PDRN is marketed, since demand is running ahead of independent evidence and the injectable versus topical distinction is easy to blur in advertising.
If you are considering PDRN, the safest step is to confirm exactly what a provider is offering, topical serum with microneedling versus an injectable, and to ask about the product's US regulatory status directly. A licensed, verified provider can explain what is and is not approved for use in the United States.